Europe
In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.
The U.S. FDA granted Roche’s Venclexta (venetoclax) full approval in combination with azacytidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia in adults 75 years or older.
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.
Moderna is working with international regulators to accelerate approval of the company’s COVID-19 vaccine candidate, mRNA-1273.
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES